JP2022506829A - エリブリンと選択的cdk4/6阻害剤との組合せを使用する癌の処置のための治療レジメン - Google Patents

エリブリンと選択的cdk4/6阻害剤との組合せを使用する癌の処置のための治療レジメン Download PDF

Info

Publication number
JP2022506829A
JP2022506829A JP2021524438A JP2021524438A JP2022506829A JP 2022506829 A JP2022506829 A JP 2022506829A JP 2021524438 A JP2021524438 A JP 2021524438A JP 2021524438 A JP2021524438 A JP 2021524438A JP 2022506829 A JP2022506829 A JP 2022506829A
Authority
JP
Japan
Prior art keywords
cancer
eribulin
inhibitor
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021524438A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022506829A5 (cg-RX-API-DMAC7.html
Inventor
ジェシカ、エイ.ソレンティノ
パトリック、ジョセフ、ロバーツ
ジェイ、コープランド、ストラム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
G1 Therapeutics Inc
Original Assignee
G1 Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G1 Therapeutics Inc filed Critical G1 Therapeutics Inc
Publication of JP2022506829A publication Critical patent/JP2022506829A/ja
Publication of JP2022506829A5 publication Critical patent/JP2022506829A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021524438A 2018-11-09 2019-11-12 エリブリンと選択的cdk4/6阻害剤との組合せを使用する癌の処置のための治療レジメン Pending JP2022506829A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862758388P 2018-11-09 2018-11-09
US62/758,388 2018-11-09
PCT/US2019/061010 WO2020097625A1 (en) 2018-11-09 2019-11-12 Therapeutic regimens for treatment of cancer using eribulin and selective cdk4/6 inhibitor combinations

Publications (2)

Publication Number Publication Date
JP2022506829A true JP2022506829A (ja) 2022-01-17
JP2022506829A5 JP2022506829A5 (cg-RX-API-DMAC7.html) 2022-11-21

Family

ID=70612537

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021524438A Pending JP2022506829A (ja) 2018-11-09 2019-11-12 エリブリンと選択的cdk4/6阻害剤との組合せを使用する癌の処置のための治療レジメン

Country Status (5)

Country Link
US (1) US20210267986A1 (cg-RX-API-DMAC7.html)
EP (1) EP3877422A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022506829A (cg-RX-API-DMAC7.html)
CN (1) CN113271977A (cg-RX-API-DMAC7.html)
WO (1) WO2020097625A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL317919A (en) 2016-12-05 2025-02-01 G1 Therapeutics Inc Preservation of immune response during chemotherapy regimens
JP7229162B2 (ja) 2017-01-06 2023-02-27 ジー1 セラピューティクス, インコーポレイテッド 癌の治療に対する併用療法
JP7853532B2 (ja) 2020-05-19 2026-04-30 ファーマコスモス ホールディング エー/エス 医学的障害を治療するためのサイクリン依存性キナーゼ阻害化合物
WO2022087018A1 (en) * 2020-10-19 2022-04-28 G1 Therapeutics, Inc. Improved fluorouracil-based multi-agent chemotherapy for treatment of metastatic colorectal cancer
CN114748480B (zh) * 2021-01-08 2023-10-20 轩竹生物科技股份有限公司 一种预防和/或治疗癌症的药物组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016501213A (ja) * 2012-12-04 2016-01-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 乳がんの処置におけるエリブリンの使用
WO2018016563A1 (en) * 2016-07-20 2018-01-25 Eisai R&D Management Co., Ltd. Use of eribulin and histone deacetylase inhibitors in the treatment of cancer
WO2018106729A1 (en) * 2016-12-05 2018-06-14 G1 Therapeutics, Inc. Preservation of immune response during chemotherapy regimens

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102186969B1 (ko) * 2010-10-25 2020-12-04 쥐원 쎄라퓨틱스, 인크. Cdk 억제제
JP6430483B2 (ja) * 2013-03-15 2018-11-28 ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. 化学療法の間の正常細胞の一時的な保護
RU2016136504A (ru) * 2014-03-03 2018-04-03 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. ПРИМЕНЕНИЕ ЭРИБУЛИНА И ИНГИБИТОРОВ mTOR В КАЧЕСТВЕ КОМБИНИРОВАННОЙ ТЕРАПИИ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ
WO2015161283A1 (en) * 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation
WO2015183961A1 (en) * 2014-05-28 2015-12-03 Eisai R&D Management Co., Ltd Use of eribulin in the treatment of cancer
EP3191098A4 (en) * 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
US20160166536A1 (en) * 2014-12-12 2016-06-16 Northwestern University Combination therapy for the treatment of cancer
US20160220569A1 (en) * 2015-02-03 2016-08-04 G1 Therapeutics, Inc. CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy
WO2018005533A1 (en) * 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Antiproliferative pyrimidine-based compounds
JP7229162B2 (ja) * 2017-01-06 2023-02-27 ジー1 セラピューティクス, インコーポレイテッド 癌の治療に対する併用療法
EP3621633A2 (en) * 2017-05-11 2020-03-18 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
EP3654967A4 (en) * 2017-07-21 2021-04-21 Eisai R&D Management Co., Ltd. USE OF EIBULIN AND CYCLINE-DEPENDENT KINASE INHIBITORS IN THE TREATMENT OF CANCER

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016501213A (ja) * 2012-12-04 2016-01-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 乳がんの処置におけるエリブリンの使用
WO2018016563A1 (en) * 2016-07-20 2018-01-25 Eisai R&D Management Co., Ltd. Use of eribulin and histone deacetylase inhibitors in the treatment of cancer
WO2018106729A1 (en) * 2016-12-05 2018-06-14 G1 Therapeutics, Inc. Preservation of immune response during chemotherapy regimens

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MOL CAN THER, vol. 17(1_Sup.), B191, JPN6023044746, 2018, ISSN: 0005186322 *
ONCOTARGET, vol. 8(48), JPN6023044745, 2017, pages 83925 - 83939, ISSN: 0005186323 *

Also Published As

Publication number Publication date
US20210267986A1 (en) 2021-09-02
EP3877422A1 (en) 2021-09-15
EP3877422A4 (en) 2022-08-24
CN113271977A (zh) 2021-08-17
WO2020097625A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
EP2739153B1 (en) Treatment of breast cancer
TWI667021B (zh) 二氫檞皮素或其醫藥上可接受之鹽、或含有彼之組合物的醫藥用途
US20210267986A1 (en) Therapeutic regimens for treatment of cancer using eribulin and selective cdk4/6 inhibitor combinations
CN112867512A (zh) 联合疗法
KR20160072261A (ko) 브로모도메인 및 엑스트라-말단 (bet) 단백질 저해제를 이용한 암 치료를 위한 조합 요법
JP2013533257A (ja) 血液癌の治療法
CA3018145C (en) TREATMENT METHOD FOR TRIPLE-NEGATIVE BREAST CANCER
CA2672933A1 (en) Method of treating cancer by a combined therapy of anticancer agents
JP7266030B2 (ja) リンパ球悪性疾患を治療するための方法
US20120308562A1 (en) Methods of treating mesothelioma with a pi3k inhibitor compound
JP7703124B1 (ja) Serd投薬レジメンの組み合わせを使用してがんを治療する方法
JP2016520665A (ja) Mps−1キナーゼ阻害剤および有糸分裂阻害剤を含む、癌の治療のための組合わせ
WO2022090443A1 (en) Administration and dose regimen for a combination of a bcl-2 inhibitor and a mcl1 inhibitor
Odhiambo et al. Preclinical evaluation of the ATR inhibitor BAY 1895344 as a radiosensitizer for head and neck squamous cell carcinoma
CN102256603B (zh) 用于在治疗中增加凋亡的有丝分裂抑制剂
JP2025535194A (ja) Kras阻害剤と組み合わせたpimキナーゼ阻害剤
EP3880207B1 (en) Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof
CN112891353B (zh) 药物组合及其用途
WO2020254299A1 (en) Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof
JP2023537290A (ja) 癌を処置するためのBcl-2阻害薬と低メチル化剤との組合せ、その使用及び医薬組成物
HK40059017A (en) Therapeutic regimens for treatment of cancer using eribulin and selective cdk4/6 inhibitor combinations
WO2021048419A1 (en) Combination therapies comprising trametinib for the treatment of cholangiocarcinoma
EP4027996A1 (en) Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma
EP4452275B1 (en) Combination of cisplatin and elimusertib for the treatment of pediatric liver cancers
US20170340629A1 (en) Masitinib combination for use in treating breast cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221111

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231031

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240531